Hydralazine hydrochloride - CAS 304-20-1
Catalog number: B0084-065607
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H8N4.HCl
Molecular Weight:
196.64
COA:
Inquire
Targets:
Others
Description:
Hydralazine HCl is a hydrochloride salt of hydralazine (Apresoline) that is a direct-acting smooth muscle relaxant with an IC50 of 1.9 mM.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-065607 100 g $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Hydralazine hydrochloride
MSDS:
Inquire
1.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.
Ruiz-Magaña MJ1, Martínez-Aguilar R1, Lucendo E1, Campillo-Davo D1, Schulze-Osthoff K2,3, Ruiz-Ruiz C1,4. Oncotarget. 2016 Mar 3. doi: 10.18632/oncotarget.7871. [Epub ahead of print]
Epigenetic therapies have emerged as promising anticancer approaches, since epigenetic modifications play a major role in tumor initiation and progression. Hydralazine, an approved vasodilator and antihypertensive drug, has been recently shown to act as a DNA methylation inhibitor. Even though hydralazine is already tested in clinical cancer trials, its mechanism of antitumor action remains undefined. Here, we show that hydralazine induced caspase-dependent apoptotic cell death in human p53-mutant leukemic T cells. Moreover, we demonstrate that hydralazine triggered the mitochondrial pathway of apoptosis by inducing Bak activation and loss of the mitochondrial membrane potential. Hydralazine treatment further resulted in the accumulation of reactive oxygen species, whereas a superoxide dismutase mimetic inhibited hydralazine-induced cell death. Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway.
2.Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.
Sharma KJ1, Rodriguez M1, Kilpatrick SJ1, Greene N1, Aghajanian P1. Hypertens Pregnancy. 2016 Feb;35(1):123-8. doi: 10.3109/10641955.2015.1117098. Epub 2016 Feb 24.
OBJECTIVE: To determine whether the incidence of hypotension or adverse fetal heart tracing (FHT) category change differed following antepartum administration of intravenous (IV) labetalol versus hydralazine.
3.Heart Failure Update: Outpatient Management.
Wojnowich K1, Korabathina R2. FP Essent. 2016 Mar;442:18-25.
Outpatient management of heart failure (HF) is aimed at treating symptoms and preventing hospitalizations and readmissions. Management is initiated in a stepwise approach. Blockade of the renin-angiotensin system is a cornerstone of therapy and should be started, along with beta blockers, as soon as the diagnosis of HF is made. Other drugs, including diuretics, aldosterone antagonists, hydralazine, and nitrates, may be added based on symptoms and American College of Cardiology/American Heart Association stage. Despite a great interest in and theoretical benefit of naturoceutical products in the mitigation of oxidative stress and HF progression, none has been proven to be beneficial, and concerns exist regarding their interactions with standard HF drugs. Other nonpharmacologic interventions, including sodium restriction, regular exercise, and/or cardiac rehabilitation, should be initiated at diagnosis. HF often is progressive, and clinicians should be aware of late stage management options, including implantable devices, cardiac transplantation, and hospice care.
4.Novel epigenetic-based therapies useful in cardiovascular medicine.
Napoli C1, Grimaldi V1, De Pascale MR1, Sommese L1, Infante T1, Soricelli A1. World J Cardiol. 2016 Feb 26;8(2):211-9. doi: 10.4330/wjc.v8.i2.211.
Epigenetic modifications include DNA methylation, histone modifications, and microRNA. Gene alterations have been found to be associated with cardiovascular diseases, and epigenetic mechanisms are continuously being studied to find new useful strategies for the clinical management of afflicted patients. Numerous cardiovascular disorders are characterized by the abnormal methylation of CpG islands and so specific drugs that could inhibit DNA methyltransferase directly or by reducing its gene expression (e.g., hydralazine and procainamide) are currently under investigation. The anti-proliferative and anti-inflammatory properties of histone deacetylase inhibitors and their cardio-protective effects have been confirmed in preclinical studies. Furthermore, the regulation of the expression of microRNA targets through pharmacological tools is still under development. Indeed, large controlled trials are required to establish whether current possible candidate antisense microRNAs could offer better therapeutic benefits in clinical practice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 94-16-6 Aminohippurate Sodium

Aminohippurate Sodium
(CAS: 94-16-6)

Aminohippurate Sodium is a diagnostic agent that is used to help differentiate and characterized organic anion transporter (OAT) isoforms. It is useful in medic...

CAS 305-03-3 Chloroambucil

Chloroambucil
(CAS: 305-03-3)

Chlorambucil (marketed as Leukeran by GlaxoSmithKline) is a chemotherapy drug that has been mainly used in the treatment of chronic lymphocytic leukemia. It is ...

CAS 297730-17-7 AVN-944

AVN-944
(CAS: 297730-17-7)

AVN-944 (VX-944) is an orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (...

CAS 465-11-2 Gamabufotalin

Gamabufotalin
(CAS: 465-11-2)

Gamabufotalin is a major bufadienolide of Chansu and has been used for cancer therapy due to its desirable metabolic stability and less adverse effect.

CAS 59865-13-3 Cyclosporine

Cyclosporine
(CAS: 59865-13-3)

Immunosuppressant; inhibits phosphatase activity of calcineurin (IC50 = 5 nM). Also inhibits formation and opening of the mitochondrial permeability transition ...

CAS 67-48-1 Choline Chloride

Choline Chloride
(CAS: 67-48-1)

Choline chloride is a quaternary ammonium salt used as an additive for animal feed, especially for chickens where it accelerates growth.

CAS 1005491-05-3 Tirasemtiv

Tirasemtiv
(CAS: 1005491-05-3)

Tirasemtiv is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with...

CAS 1478364-68-9 PXS 4728A

PXS 4728A
(CAS: 1478364-68-9)

PXS 4728A is a VAP-1 (aka SSAO/AOC3) inhibitor with IC50 values 5 nM in the clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Studies sh...

BVT 2733
(CAS: 376640-41-4)

BVT 2733 is a non-steroidal small molecule as a a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor (IC = 96 ± 14 nM w).

CP-664511
(CAS: 379692-00-9)

CP-664511 is a potent compound that is a alpha4beta1/vascular cell adhesion molecule-1 (VCAM-1) inhibitor which has therapeutic potential in treating allergic a...

CAS 865783-95-5 ON-013100

ON-013100
(CAS: 865783-95-5)

ON-013100, a cell cycle inhibitor, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important molecules, i...

CAS 479-98-1 Aucubin

Aucubin
(CAS: 479-98-1)

Aucubin is an iridoid glycoside with a wide range of biological activities, including anti-inflammatory, anti-microbial, anti-algesic as well as anti-tumor acti...

CGP 43182
(CAS: 150379-37-6)

CGP 43182, a dioxaspiro compound, has been found to a IIA sPLA2 inhibitor that could have potential anti-inflammatory effect and also in influencing the synergi...

CFI-401870
(CAS: 1599460-95-3)

CFI-401870, an azabicyclo derivative, has been found to be a TTK inhibitor that could be significant in anticancer studies. IC50 < 10 nM.

Lotilaner
(CAS: 1369852-71-0)

Lotilaner is an insecticide and veterinary drug.

CAS 67416-61-9 AKBA

AKBA
(CAS: 67416-61-9)

AKBA is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.

CAS 920014-72-8 Setmelanotide

Setmelanotide
(CAS: 920014-72-8)

Setmelanotide is a melanocortin 4 receptor (MC4R) agonist (EC50= 0.27 nM for human MC4R) that is used as a peptide drug and investigational anti-obesity medicat...

CAS 212201-70-2 Ipfencarbazone

Ipfencarbazone
(CAS: 212201-70-2)

Ipfencarbazone is a non-hormonal translocation-type herbicide. It is thought to inhibit the biosynthesis of very long chain fatty acids in plants. Preparations ...

CAS 130273-87-9 15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester

15(R)-17-phenyl trinor Prostaglandin F2α
(CAS: 130273-87-9)

15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester is a potential impurity in most commercial preparations of the latanoprost bulk drug product. The IC50 ...

Azoramide
(CAS: 932986-18-0)

Azoramide is a modulator of the unfolded protein response with antidiabetic activity. It is a dual-function endoplasmic reticulum (ER) modulator in vitro. It im...

Chemical Structure

CAS 304-20-1 Hydralazine hydrochloride

Quick Inquiry

Verification code

Featured Items